Novus creatus - Company finances
- The company has not submitted financial data for these years: 2023.
|
EUR
|
2019
From: 2019-09-12
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | 0 | - | 431 | 36,254 | 289,140 | 78,476 |
| Profit before tax | - | - | - | - | 269,982 | 6,809 |
| Net profit | -88 | -2,311 | -14,508 | 13,421 | 256,483 | 6,400 |
| Equity | 2,462 | 151 | -13,644 | -199 | 256,284 | 29,026 |
| Liabilities | 164 | 5,228 | 19,558 | 1,924 | 16,323 | 3,975 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 782 |
| Current assets | 2,559 | 5,305 | 5,866 | 1,629 | 272,511 | 32,219 |
| Total assets | 2,559 | 5,305 | 5,866 | 1,629 | 272,511 | 33,001 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | - | 1,608 | 44,946 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | - | +8311.6% | - | -72.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -3.4% | -43.6% | -247.3% | 823.9% | 94.1% | 19.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -3.6% | -1530.5% | - | - | 100.1% | 22.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | -3366.1% | 37.0% | 88.7% | 8.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 93.4% | 8.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 34.6 | - | - | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | 216 | 18,127 | 144,570 | 33,633 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Novus creatus - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-03-15 | 2026-03-15 | 0.02 |
| 2026-01-21 | 2026-02-11 | 0.13 |
| 2025-02-18 | 2025-04-10 | 0.81 |
| 2025-01-22 | 2025-02-12 | 0.81 |
| 2024-11-18 | 2024-12-15 | 0.92 |
| 2024-10-24 | 2024-11-10 | 0.92 |
| 2024-10-16 | 2024-10-23 | 455.95 |
| 2024-09-17 | 2024-09-25 | 316.03 |
| 2022-01-28 | 2022-02-13 | 2.25 |
| 2022-01-18 | 2022-01-26 | 130.22 |
| 2021-12-20 | 2021-12-28 | 260.46 |
| 2021-12-17 | 2021-12-19 | 130.24 |
| 2021-12-16 | 2021-12-16 | 0.02 |
| 2021-11-16 | 2021-12-08 | 0.02 |
| 2021-10-18 | 2021-11-04 | 0.02 |
| 2021-09-16 | 2021-10-05 | 0.02 |
Novus creatus - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-25 | 2025-01-25 | 0.67 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Novus creatus, UAB (code 305249916) is a Private Limited Liability Company engaged in the retail sale of pharmaceutical products. In 2025, the company generated revenue of €78.5K and net profit of €6.4K, with a profit margin of 8.2%. Revenue declined by 72.9% year on year from €289.1K in 2024, when net profit reached €256.5K and the profit margin was 88.7%. The 2025 balance sheet shows total assets of €33.0K, equity of €29.0K and liabilities of €4.0K, indicating a strongly equity-financed structure. Key ratios for 2025 include return on equity of 22.1%, return on assets of 19.4%, debt-to-equity of 0.14 and asset turnover of 2.38x. Productivity metrics point to revenue per employee of €39.2K and profit per employee of €3.2K. Overall, the latest year shows a much smaller operating base than 2024, but the company remained profitable and maintained a solid equity position.